• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of interferon and cytokine research: The official journal of the International Society for Interferon and Cytokine Research >Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience
【24h】

Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience

机译：在所有治疗患者中，目前在国民治疗政策中的调理导致令人惊讶的HCV病毒抑制：现实生活埃及经验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this study was to retrospectively analyze the outcome of an unscheduled change in national Egyptian policies for the treatment of hepatitis C virus (HCV), which was transpired as a result of a reduction in interferon supplies, and to manage patients who already started interferon-based therapy. After completing a priming 4-weeks course of sofosbuvir/pegylated interferon/ribavirin (SOF/PEG IFN/RBV), a 12-weeks course of sofosbuvir/daclatasvir (SOF/DCV) combination was initiated. We evaluated the sustained virologic response at 12 weeks posttreatment (SVR12) for 2 groups of patients; Group 1, which included patients who had the previous regimen with IFN priming, and group 2, which included the first consecutive group of patients who received SOF/DCV for 12 weeks from the start without IFN priming. All group 1 patients (1,214 patients) achieved SVR12 (100%) and this was statistically significant when compared with the overall SVR12 in group 2 [8,869 patients with sustained virologic response [SVR] of 98.9%] (P value 0.001). No serious adverse events were reported in both groups. In this real-life treatment experience, interferon-based directly acting antiviral treatment with SOF/PEG IFN/RBV as a priming for 4 weeks, followed by SOF/DCV combination for 12 weeks, led to HCV viral suppression in all treated patients.
机译：本研究的目的是回顾性地分析国家埃及治疗丙型肝炎病毒（HCV）的非洲埃及政策的结果，这是由于干扰素供应的减少而被迁移，并管理已经开始的患者基于干扰素的疗法。在完成Sofosbuvir / Pegymated干扰素/利巴韦林（SOF / PEG IFN / RBV）的引发4周后，启动了12周的Sofosbuvir / daclataSVIR（SOF / DCV）组合。我们在2组患者的12周内评估了持续的病毒学反应（SVR12）;第1组包括具有IFN引发的先前方案的患者和第2组，其中包括从一开始就收到SOF / DCV的第一个连续患者，而没有IFN引发。所有第1组患者（1,214名患者）达到了SVR12（100％），与第2组的总SVR12相比，这是统计学意义[8,869名持续病毒学反应的8,869名患者[SVR]为98.9％]（P值<0.001）。两组都没有报告严重的不良事件。在这种真实的处理经验中，基于干扰素的直接作用抗病毒治疗用SOF / PEG IFN / RBV作为灌注4周，其次是SOF / DCV组合12周，导致所有治疗患者的HCV病毒抑制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号